Hawkins (HWKN) Q4 2026 earnings review
Milestone Revenues, But Acquisitions Drag Earnings Down
Hawkins surpassed $1 billion in annual revenue for the first time, fueled by aggressive acquisitions in the Water Treatment segment. However, the top-line success masks a deteriorating bottom line. Q4 Net Income dropped 5% YoY and full-year EPS fell 3%, reversing a seven-year growth streak. The culprit: heavy debt loads, amortization, and earnout liabilities tied to the WaterSurplus acquisition. While management attempts to direct attention to 'pro forma' adjustments and a 22% jump in operating cash flow, the reality is that acquisition costs and competitive pricing in the Food & Health Sciences segment are currently destroying GAAP earnings growth.
🐂 Bull Case
Water Treatment sales surged 16% in Q4 and 22% for the year, largely driven by six recent acquisitions. The segment now accounts for 50% of total revenue and 56% of operating income, solidifying Hawkins' market position.
Operating cash flow jumped 30% to $144.3M in FY26. Management is deploying this efficiently, targeting a reduction in leverage to roughly 1.0x Adjusted EBITDA by FY27, which should ease the current interest expense burden.
🐻 Bear Case
The WaterSurplus deal has significantly bloated expenses. A $4.4M increase in Q4 amortization, interest, and earnout accretion entirely wiped out the operating profit gains from higher sales.
F&HS sales were flat in Q4 (+<1%) and down 1% for the year. More alarmingly, gross profit in this segment fell 6% due to severe competitive pricing pressures.
⚖️ Verdict: ⚪
Neutral. The company is successfully executing its roll-up strategy in Water Treatment, and cash generation remains robust. However, until the debt is paid down and acquisition-related expenses roll off, EPS growth will remain constrained.
Key Themes
Earnings Dilution from Aggressive M&A
Reversing. EPS dropped from $0.78 in 25Q4 to $0.74 in 26Q4. Management explicitly noted an approximately $16.5M full-year hit to earnings stemming from amortization, interest expense, and fair value accretion of earnout liabilities from six acquisitions (primarily WaterSurplus). While management promotes a 'pro forma EPS' metric showing 9% growth, investors must monitor whether these 'one-time' acquisition impacts become a permanent drag on GAAP profitability.
Food & Health Sciences Segment is Lagging
Decelerating. The F&HS segment was the clear laggard, with Q4 sales growing less than 1% YoY to $88.6M. Over the full fiscal year, segment gross profit dropped $4.6M (6%). Management pointed to softness in nutrition end markets and competitive pricing pressures offsetting agricultural volume gains. This structural margin compression requires immediate attention.
Water Treatment Roll-Up Strategy Working
Stable. The Water Treatment segment continues to anchor the business, posting 16% YoY growth in Q4. FY26 segment sales surged 22%, supported heavily by $83.3M from acquired businesses. By incorporating WaterSurplus's filtration media and equipment offerings, Hawkins has built a comprehensive product portfolio that creates stickier customer relationships and cross-selling opportunities.
Macro Impact: LIFO Reserves and Material Costs
Stable. Material costs are creeping back up. During FY26, the LIFO reserve increased, reducing gross profits by $1.5M ($0.8M of which hit in Q4). This contrasts with FY25, when a decreasing LIFO reserve actually boosted gross profit by $1.6M. If commodity prices continue rising, margins will rely heavily on Hawkins' pricing power, which currently appears strained in the Food segment.
Other KPIs
Stable. Up 6% YoY from $168.9M. While GAAP net income retreated, Adjusted EBITDA demonstrates that the core cash-generating capacity of the acquired businesses is intact, stripping out the heavy $21.3M intangible amortization load.
Accelerating. A massive 30% increase ($33.2M) over the prior year. This robust cash conversion allowed Hawkins to fund $167.1M in acquisitions (including WaterSurplus) while only increasing net debt borrowings by $95.0M.
Reversing. Leverage spiked from 0.86x at the end of FY25 to 1.37x at the end of FY26, driven by a $95M net increase in debt to fund the WaterSurplus and five tuck-in acquisitions. Total debt stands at $244.0M.
Guidance
Management expects EPS to grow in FY27, signaling an end to the temporary EPS compression seen in FY26. However, no specific range was provided, leaving uncertainty around the exact timeline for accretion from the WaterSurplus acquisition.
Accelerating. The company is pivoting from an aggressive M&A accumulation phase to balance sheet repair. Reaching ~1.0x by the end of FY27 (down from 1.37x today) implies significant planned debt paydowns fueled by operating cash flow.
Stable. This aligns with the 25% reported for FY26 and 26% reported for FY25, offering no material headwind or tailwind to the bottom line.
Key Questions
WaterSurplus Accretion Timeline
With $16.5M in added expenses related to acquisitions dragging down FY26 EPS, exactly when in FY27 do you expect the WaterSurplus integration to become accretive to GAAP earnings on a run-rate basis?
Pricing Power in Food & Health Sciences
Gross margins in F&HS dropped significantly due to competitive pricing pressures. Are these pricing adjustments permanent baseline resets, or do you have a strategy to recover these margins in FY27?
Earnout Liability Management
The earnout liability sits at nearly $45 million long-term and $4.5 million short-term. How much volatility should investors expect in the SG&A line going forward related to fair value accretion of these earnouts?